| First Author | Wang L | Year | 2019 |
| Journal | Sci Rep | Volume | 9 |
| Issue | 1 | Pages | 15762 |
| PubMed ID | 31673032 | Mgi Jnum | J:284885 |
| Mgi Id | MGI:6389488 | Doi | 10.1038/s41598-019-52265-8 |
| Citation | Wang L, et al. (2019) Targeting ERbeta in Macrophage Reduces Crown-like Structures in Adipose Tissue by Inhibiting Osteopontin and HIF-1alpha. Sci Rep 9(1):15762 |
| abstractText | Proinflammatory processes in adipose tissue contribute to development of breast cancer and insulin resistance. Crown-like structures (CLS) are histologic hallmarks of the proinflammatory process in adipose tissue. CLS are microscopic foci of dying adipocytes surrounded by macrophages mostly derived from monocytes in blood. Estrogen receptor beta (ERbeta) is expressed in microglia, macrophages within the central nervous system (CNS), where it evokes an anti-inflammatory response. The present study investigates the function of ERbeta in macrophages within CLS. We report that even though monocytes in the blood have no detectable levels of ERbeta, macrophages in CLS do express ERbeta. In ERbeta-/- mice, there was a significant increase in the number of CLS in both subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT). CLS in these mice were dominated by pro-inflammatory macrophages (M1 macrophages) with higher expression of osteopontin (OPN) and an increase in number of proliferating macrophages. In mice made obese by Western diet, treatment with an ERbeta selective agonist (LY3201) reduced the number of CLS in both SAT and VAT with downregulation of OPN, activated hypoxia-inducible factor-1alpha (HIF-1alpha), proliferation and upregulation prolyl hydroxylase 2 (PHD2), the enzyme which prevents activation of HIF1alpha, in macrophages. We conclude that ERbeta expression is induced in macrophages in CLS within adipose tissue where it plays a pivotal role in suppression of CLS. Thus ERbeta agonists may be used to alleviate CLS-related breast cancer and insulin resistance in adipose tissue. |
